I am a
Home I AM A Search Login

Papers of the Week

Papers: 8 Jun 2019 - 14 Jun 2019

Human Studies, Pharmacology/Drug Development

2019 Jun 04

BMJ Open



Efficacy and safety of cannabidiol followed by an open label add-on of tetrahydrocannabinol for the treatment of chronic pain in patients with rheumatoid arthritis or ankylosing spondylitis: protocol for a multicentre, randomised, placebo-controlled study


Hendricks O, Andersen T E, Christiansen A A, Primdahl J, Hauge E M, Ellingsen T, Horsted T I, Bachmann A G, Loft A G, Bojesen A B, Østergaard M, Hetland M L, Krogh N S, Roessler K K, Petersen K H
BMJ Open. 2019 Jun 04; 9(6):e028197.
PMID: 31167870.


Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) are chronic, systemic, inflammatory diseases, primarily in the musculoskeletal system. Pain and fatigue are key symptoms of RA and AS. Treatment presents a clinical challenge for several reasons, including the progressive nature of the diseases and the involvement of multiple pain mechanisms. Moreover, side effects of pain treatment pose an implicit risk. Currently, no well-controlled studies have investigated how medical cannabis affects pain and cognitive functions in RA and AS. The present study aims to evaluate the efficacy and safety of medical cannabis in the treatment of persistent pain in patients with RA and AS with low disease activity.